MicroRNA Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 15.60 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
MicroRNA Market Analysis
The microRNA market is projected to register a CAGR of 15.6% during the forecast period.
- The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. In addition to vaccinations against SARS-CoV-2 infection that had been approved, microRNAs were found to be a potential alternative for combating this new virus.
- According to the article published in March 2021 in PubMed, various microRNAs bind to the SARS-CoV-2 genome and limit its post-transcriptional expression, reducing the severity of COVID-19 disease. In addition, among all miRNAs, miR-21-3p was found to have the best binding to the human coronavirus genome. In the post-pandemic situation, the market is expected to witness growth due to the increase in chronic diseases that require novel therapies and the rise in advancements in microRNA technologies.
- The factors propelling the growth of the microRNA market are the increasing prevalence of chronic diseases, the advancement and adoption of next-generation sequencing methods and their applications in various fields, and the increasing adoption of microRNA as a biomarker. The rising prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, etc., and rare diseases are the key factors driving the growth of the market over the forecast period.
- For instance, according to the American Cancer Society 2023 Statistics, 1.9 million new cancer cases are anticipated to be recorded in the United States in 2023, a rise from 1.8 million in 2021. In addition, the adoption of microRNA in cancer treatment is expected to be aided by extensive research activities. For instance, as per the article published in February 2022 in PubMed, the identification and characterization of new cancer-relevant miRs may be used to facilitate patient diagnosis and prognosis of different tumors. Moreover, miR profiles can define relevant tumoral subtypes. Thus, the study of tumors with the aid of microRNA is expected to be one of the major factors boosting market growth.
- Moreover, key players have entered into several strategic initiatives such as mergers, acquisitions, and partnerships to expand their product availability across the globe. For instance, in January 2022, BIORCHESTRA, a South Korean biopharmaceutical company, entered into a partnership agreement with SK Biopharmaceuticals to accelerate research and development into novel therapeutic compounds that target microRNAs.
- Similarly, in February 2021, Aurora Science, an Italian biotech investment company, funded USD 22.46 million to InteRNA Technologies for developing microRNA. InteRNA Technologies is a clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in the initiation and progression of human diseases, with a focus on cancer. These microRNA compounds, chosen through its top-tier microRNA discovery and functional validation technology platform and equipped with a third-generation drug delivery formulation, can launch a coordinated anti-cancer assault by simultaneously interacting with several signal transduction targets.
- Thus, due to the increase in research and development activities, the surge in investments, and the growing burden of chronic disease that utilizes the application of microRNA for therapies, the studied market is expected to witness growth over the forecast period. However, the safety and toxicity issues of microRNAs are likely to hinder the growth of the market over the forecast period.
MicroRNA Market Trends
Real-Time Polymerase Chain Reaction Segment is Expected to Witness a Significant Growth in the Market Over the Forecast Period
- The polymerase chain reaction is based on using the ability of DNA polymerase to synthesize a new strand of DNA complementary to the offered template strand. The polymerase chain reaction is widely used to rapidly make millions to billions of copies of a specific DNA sample.
- The factors propelling the growth of real-time polymerase chain reaction are the rising prevalence of chronic diseases, increasing application of polymerase chain reaction in drug development, clinical diagnostics, and rapid technological advancements such as the development of high-performance and superior quantitative PCR (qPCR) and digital PCR (dPCR) systems.
- As per the article published in February 2022 in the MDPI journal, quantitative reverse-transcription polymerase chain reaction (qRT-PCR) is an effective and common method for sensitive and specific analysis of microRNA from biological fluids, such as plasma or serum.
- Similarly, as per the article published in September 2022 in Kargar, quantitative PCR is the most frequently used method of measuring expression levels of microRNA. Also, various technological advancements in PCR systems are widely accepted for the quantification of microRNAs. For instance, as per the article published in June 2022 in PubMed, circulating microRNAs have been suggested as particular illness biomarkers. The current gold standard method for assessing microRNA expression from various sources is quantitative real-time PCR (RT-qPCR).
- Furthermore, government funding for clinical research which also includes PCR-based studies, is expected to drive market growth. For instance, as per the NIH 2022 update, the estimated research funding for clinical research is USD 18.38 billion in 2023. Thus, the increase in research and development in PCR technologies involving the development of microRNA is expected to drive segment growth over the forecast period.
North America is Expected to Have the Significant Market Share Over the Forecast Period
- North America is expected to hold a significant market share in the studied market due to the increase in incidences of chronic diseases and rising demand for next-generation and microRNA services and applications in drug development.
- Further, the other factors fueling the market growth are the adoption of the latest technology and the established research infrastructure for proteomics and genomics. The rising number of cardiovascular diseases in the region is the key driving factor in the growth of the microRNA market. As per the data from the CARES Report 2021, 97.6% of adults and 2.4% of children were reported with out-of-hospital cardiac arrest in 2021 in the United States.
- In addition, the increasing drug and patent approvals from the FDA in the region are also contributing to the growth of the market. For instance, in December 2021, InteRNA Technologies received Investigational New Drug approval from the United States Food and Drug Administration for its Phase I clinical trial evaluating the lead microRNA candidate, INT-1B3, in patients with advanced solid tumors. This approval enables InteRNA to expand the number of clinical sites and facilitate the enrollment of patients for the dose-expansion part of the trial in the United States.
- Moreover, the presence of key players, such as Illumina Inc., Thermo Fisher Scientific, etc., and an increase in research and development spending by companies to develop innovative and advanced products in the United States are expected to drive regional growth. For instance, in March 2021, DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory from Interpace Biosciences, Inc. Acquisition of this CLIA-certified lab facility significantly expands DiamiR's capabilities to develop and commercialize their microRNA-based tests for early detection, differential diagnosis, prediction of progression and monitoring of brain health and other conditions.
- Thus, the rising number of chronic disease cases, new product launches, and increasing product approvals are likely to increase the growth of the microRNA market in the studied region.
MicroRNA Industry Overview
The microRNA market is competitive in nature, with several players across the globe. With the increase in research and development activity, many regional players are expected to be part of the microRNA market over the forecast period. Some of the key players in the market are Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., PerkinElmer, Inc., and Takara Bio, Inc.
MicroRNA Market Leaders
Qiagen N.V.
Thermo Fisher Scientific, Inc.
PerkinElmer, Inc.
Illumina, Inc.
Takara Bio, Inc
*Disclaimer: Major Players sorted in no particular order
MicroRNA Market News
- August 2022: Singapore-based biotechnology company, MiRXES, launched a series of new capabilities, including an Industry 4.0 (i4.0) manufacturing facility, two new laboratories, and a collaborative multi-cancer screening research project. The new developments are aligned with MiRXES' goal of advancing its research and production capabilities to develop miRNA-based disease detection tests.
- February 2022: Researchers at the University of Illinois Urbana developed a new microRNA point-of-care test for cancer detection. The test uses nanoparticles to capture tumor-specific microRNAs (miRNAs) in human serum.
Micro RNorth America Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Rise in Research and Development
4.3 Market Restraints
4.3.1 Safety and Toxicity Issues of microRNA
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Technology
5.1.1 Real Time Polymerase Chain Reaction
5.1.2 Microarray
5.1.3 Next Generation Sequencing (NGS)
5.1.4 Immunoassay
5.2 By Application
5.2.1 Cancer
5.2.2 Immunological Disorder
5.2.3 Infectious Diseases
5.2.4 Cardiovascular Disease
5.2.5 Neurological Disease
5.2.6 Other Applications
5.3 By End-User
5.3.1 Academic and Research Institutes
5.3.2 Biopharmaceutical Companies
5.3.3 Contract Research Organizations
5.3.4 Diagnostic Centers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific, Inc.
6.1.2 Horizon Discovery Ltd.
6.1.3 QIAGEN
6.1.4 BioGenex
6.1.5 GeneCopoeia, Inc.
6.1.6 NanoString
6.1.7 Quantabio
6.1.8 SeqMatic LLC
6.1.9 OriGene Technologies, Inc.
6.1.10 Illumina, Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
MicroRNA Industry Segmentation
As per the scope of the report, microRNA is a small RNA segment that suppresses gene expression by binding to complementary messenger RNA segments and interfering with protein production during translation. MicroRNA detection is considerably important in the diagnosis and treatment of the disease and in studying the function of microRNA.
The microRNA market is segmented by technology (real-time polymerase chain reaction, microarray, next-generation sequencing (NGS), and immunoassay), application (cancer, infectious diseases, cardiovascular disease, immunological disorder, neurological diseases, and others), end-user (academic and research institutes, biopharmaceutical companies, contract research organizations, and diagnostic centers), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD million) for the above segments.
| By Technology | |
| Real Time Polymerase Chain Reaction | |
| Microarray | |
| Next Generation Sequencing (NGS) | |
| Immunoassay |
| By Application | |
| Cancer | |
| Immunological Disorder | |
| Infectious Diseases | |
| Cardiovascular Disease | |
| Neurological Disease | |
| Other Applications |
| By End-User | |
| Academic and Research Institutes | |
| Biopharmaceutical Companies | |
| Contract Research Organizations | |
| Diagnostic Centers |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Micro RNorth America Market Research FAQs
What is the current MicroRNA Market size?
The MicroRNA Market is projected to register a CAGR of 15.60% during the forecast period (2024-2029)
Who are the key players in MicroRNA Market?
Qiagen N.V., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Illumina, Inc. and Takara Bio, Inc are the major companies operating in the MicroRNA Market.
Which is the fastest growing region in MicroRNA Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in MicroRNA Market?
In 2024, the North America accounts for the largest market share in MicroRNA Market.
What years does this MicroRNA Market cover?
The report covers the MicroRNA Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the MicroRNA Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
MicroRNA Industry Report
Statistics for the 2024 MicroRNA market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. MicroRNA analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
